The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate
the health and economic outcomes of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive NMIBC. Complete details of ICER’s systematic literature search and protocol, as well as the methodology and model structure for the economic evaluation are available on ICER’s website at https://icer.org/assessment/bladder-cancer-2020/.
In this report, we present the summary of our findings and highlights of the policy discussion with key stakeholders held at a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (CEPAC) on November 20, 2020